148 related articles for article (PubMed ID: 38360598)
21. Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis.
Sadowski SM; Boufraqech M; Zhang L; Mehta A; Kapur P; Zhang Y; Li Z; Shen M; Kebebew E
Oncotarget; 2015 Jul; 6(20):18038-49. PubMed ID: 25945839
[TBL] [Abstract][Full Text] [Related]
22. HN1 promotes tumor growth and metastasis of anaplastic thyroid carcinoma by interacting with STMN1.
Pan Z; Fang Q; Li L; Zhang Y; Xu T; Liu Y; Zheng X; Tan Z; Huang P; Ge M
Cancer Lett; 2021 Mar; 501():31-42. PubMed ID: 33359451
[TBL] [Abstract][Full Text] [Related]
23. TWIST1/miR-584/TUSC2 pathway induces resistance to apoptosis in thyroid cancer cells.
Orlandella FM; Di Maro G; Ugolini C; Basolo F; Salvatore G
Oncotarget; 2016 Oct; 7(43):70575-70588. PubMed ID: 27661106
[TBL] [Abstract][Full Text] [Related]
24. SIRT7 Regulates the Vascular Smooth Muscle Cells Proliferation and Migration via Wnt/
Zheng J; Chen K; Wang H; Chen Z; Xi Y; Yin H; Lai K; Liu Y
Biomed Res Int; 2018; 2018():4769596. PubMed ID: 30627559
[TBL] [Abstract][Full Text] [Related]
25. The sonic hedgehog signaling pathway maintains the cancer stem cell self-renewal of anaplastic thyroid cancer by inducing snail expression.
Heiden KB; Williamson AJ; Doscas ME; Ye J; Wang Y; Liu D; Xing M; Prinz RA; Xu X
J Clin Endocrinol Metab; 2014 Nov; 99(11):E2178-87. PubMed ID: 25078145
[TBL] [Abstract][Full Text] [Related]
26. Knockdown of HCP5 exerts tumor-suppressive functions by up-regulating tumor suppressor miR-128-3p in anaplastic thyroid cancer.
Chen J; Zhao D; Meng Q
Biomed Pharmacother; 2019 Aug; 116():108966. PubMed ID: 31102936
[TBL] [Abstract][Full Text] [Related]
27. Long noncoding RNA MALAT1 knockdown inhibits progression of anaplastic thyroid carcinoma by regulating miR-200a-3p/FOXA1.
Gou L; Zou H; Li B
Cancer Biol Ther; 2019; 20(11):1355-1365. PubMed ID: 31500506
[TBL] [Abstract][Full Text] [Related]
28. [Effect of IL-11 on the invasive and metastatic abilities of anaplastic thyroid carcinoma cells].
Jiang YE; Zhong ZM; Chen X; Wang W; Luo JZ; Wang SQ; Chu HY; Sun CZ
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2018 Apr; 53(4):286-291. PubMed ID: 29747254
[No Abstract] [Full Text] [Related]
29. Laminin-5γ-2 (LAMC2) is highly expressed in anaplastic thyroid carcinoma and is associated with tumor progression, migration, and invasion by modulating signaling of EGFR.
Garg M; Kanojia D; Okamoto R; Jain S; Madan V; Chien W; Sampath A; Ding LW; Xuan M; Said JW; Doan NB; Liu LZ; Yang H; Gery S; Braunstein GD; Koeffler HP
J Clin Endocrinol Metab; 2014 Jan; 99(1):E62-72. PubMed ID: 24170107
[TBL] [Abstract][Full Text] [Related]
30. Targeting Super-Enhancer-Driven Oncogenic Transcription by CDK7 Inhibition in Anaplastic Thyroid Carcinoma.
Cao X; Dang L; Zheng X; Lu Y; Lu Y; Ji R; Zhang T; Ruan X; Zhi J; Hou X; Yi X; Li MJ; Gu T; Gao M; Zhang L; Chen Y
Thyroid; 2019 Jun; 29(6):809-823. PubMed ID: 30924726
[No Abstract] [Full Text] [Related]
31. BET bromodomain inhibitor JQ1 modulates microRNA expression in thyroid cancer cells.
Mio C; Conzatti K; Baldan F; Allegri L; Sponziello M; Rosignolo F; Russo D; Filetti S; Damante G
Oncol Rep; 2018 Feb; 39(2):582-588. PubMed ID: 29251329
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of RYBP inhibits proliferation, invasion, and chemoresistance to cisplatin in anaplastic thyroid cancer cells via the EGFR pathway.
Tong AH; Tan J; Zhang JH; Xu FJ; Li FY; Cao CY
J Biochem Mol Toxicol; 2019 Feb; 33(2):e22241. PubMed ID: 30431689
[TBL] [Abstract][Full Text] [Related]
33. Loss of MADD expression inhibits cellular growth and metastasis in anaplastic thyroid cancer.
Saini S; Sripada L; Tulla K; Kumar P; Yue F; Kunda N; Maker AV; Prabhakar BS
Cell Death Dis; 2019 Feb; 10(2):145. PubMed ID: 30760700
[TBL] [Abstract][Full Text] [Related]
34. DEP domain containing 1B (DEPDC1B) exerts the tumor promoter in hepatocellular carcinoma through activating p53 signaling pathway via kinesin family member 23 (KIF23).
Shen E; Zhang J; Lu Y
Bioengineered; 2022 Jan; 13(1):1103-1114. PubMed ID: 34983303
[TBL] [Abstract][Full Text] [Related]
35. The effects of Abemaciclib on cell cycle and apoptosis regulation in anaplastic thyroid cancer cells.
Abutorabi ES; Poursheikhani A; Kashani B; Shamsaiegahkani S; Haghpanah V; Bashash D; Mousavi SA; Momeny M; Ghaffari SH
Mol Biol Rep; 2023 May; 50(5):4073-4082. PubMed ID: 36877344
[TBL] [Abstract][Full Text] [Related]
36. S100A8 is a novel therapeutic target for anaplastic thyroid carcinoma.
Reeb AN; Li W; Sewell W; Marlow LA; Tun HW; Smallridge RC; Copland JA; Spradling K; Chernock R; Lin RY
J Clin Endocrinol Metab; 2015 Feb; 100(2):E232-42. PubMed ID: 25423568
[TBL] [Abstract][Full Text] [Related]
37. BRAFV600E restructures cellular lactylation to promote anaplastic thyroid cancer proliferation.
Wang X; Ying T; Yuan J; Wang Y; Su X; Chen S; Zhao Y; Zhao Y; Sheng J; Teng L; Luo C; Wang W
Endocr Relat Cancer; 2023 Aug; 30(8):. PubMed ID: 37184950
[TBL] [Abstract][Full Text] [Related]
38. SIRT7 depletion inhibits cell proliferation, migration, and increases drug sensitivity by activating p38MAPK in breast cancer cells.
Chen KL; Li L; Yang FX; Li CM; Wang YR; Wang GL
J Cell Physiol; 2018 Sep; 233(9):6767-6778. PubMed ID: 29231244
[TBL] [Abstract][Full Text] [Related]
39. Knockdown of S100A4 blocks growth and metastasis of anaplastic thyroid cancer cells in vitro and in vivo.
Zhang K; Yu M; Hao F; Dong A; Chen D
Cancer Biomark; 2016 Sep; 17(3):281-291. PubMed ID: 27802204
[TBL] [Abstract][Full Text] [Related]
40. LncRNA AFAP-AS1 promotes anaplastic thyroid cancer progression by sponging miR-155-5p through ETS1/ERK pathway.
Ning M; Qin S; Tian J; Wang Y; Liu Q
Bioengineered; 2021 Dec; 12(1):1543-1554. PubMed ID: 33999777
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
